About 50% of Americans have hypertension, yet WHICH is a preferred anti-hypertensive strategy is a random process. And pharmacogenomics may not be needed. Join host, Geoff Wall, as he evaluates a recent study evaluating the role of personalized medication selection for persons with hypertension.
 
The GameChanger
Although no genetic markers exist to determine optimal hypertensive pharmacotherapy, initial and secondary hypertensive therapy does impact outcomes. A personalized approach does produce a greater reduction in blood pressure.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Reference
Sundström J, Lind L, Nowrouzi S, et al. Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial. JAMA. 2023;329(14):1160–1169. doi:10.1001/jama.2023.3322

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
 
 
CE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the results of the PHYSIC study
2. Discuss the limitations of the PHYSIC study

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-205-H01-P
Initial release date: 5/22/2023
Expiration date: 5/22/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram